Our team

Colin Love

Non-Executive Director

Colin A. Love, PhD is the Chief Operating Officer and co-founder of Replimune, a biotechnology company developing novel oncolytic immunotherapies, where he has served since October 2015. Dr. Love has over 30 years’ experience developing and launching biotechnology products. Since December 2014, he has provided consultancy support to a range of life science companies, from small gene therapy start-ups to large established biotechnology companies. From 2011 to 2014, Dr. Love was a Vice President of Clinical Operations at Amgen, where he was responsible for the development of T-VEC (Imlygic), an oncolytic vaccine. Dr. Love was previously Senior Vice President of Product Development at BioVex Group, Inc., a privately held biotechnology company developing T-VEC, from 2000 to 2011 until its acquisition by Amgen. Prior to joining BioVex, he held leadership positions in manufacturing and development at Celltech plc (now UCB Celltech) from 1992 to 2000, and previously held manufacturing, and research and development positions with Serono Diagnostics (now Merck KGaA) and Amersham International plc (now GE Healthcare).

Connect with Colin:

We are looking for talented people to join the team